Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
April 12, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Stephen T. Wrobleski, Shuqun Lin, Katerina Leftheris, Liqi He, Steven P. Seitz, Tai-An Lin, Wayne Vaccaro